Morning vs evening light treatment of patients with winter depression.

Department of Psychiatry, Oregon Health Sciences University, Portland 97201-3098, USA.
Archives of General Psychiatry (Impact Factor: 13.75). 11/1998; 55(10):890-6. DOI: 10.1001/archpsyc.55.10.890
Source: PubMed

ABSTRACT According to the phase-shift hypothesis for winter depression, morning light (which causes a circadian phase advance) should be more antidepressant than evening light (which causes a delay). Although no studies have shown evening light to be more antidepressant than morning light, investigations have shown either no difference or morning light to be superior. The present study assesses these light-exposure schedules in both crossover and parallel-group comparisons.
Fifty-one patients and 49 matched controls were studied for 6 weeks. After a prebaseline assessment and a light/dark and sleep/wake adaptation baseline week, subjects were exposed to bright light at either 6 to 8 AM or 7 to 9 PM for 2 weeks. After a week of withdrawal from light treatment, they were crossed over to the other light schedule. Dim-light melatonin onsets were obtained 7 times during the study to assess circadian phase position.
Morning light phase-advanced the dim-light melatonin onset and was more antidepressant than evening light, which phase-delayed it. These findings were statistically significant for both crossover and parallel-group comparisons. Dim-light melatonin onsets were generally delayed in the patients compared with the controls.
These results should help establish the importance of circadian (morning or evening) time of light exposure in the treatment of winter depression. We recommend that bright-light exposure be scheduled immediately on awakening in the treatment of most patients with seasonal affective disorder.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This research examined the impact of daylight exposure on the health of office workers from the perspective of subjective well-being and sleep quality as well as actigraphy measures of light exposure, activity, and sleep-wake patterns.
    Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine 01/2014; 10(6):603-11. · 2.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Depressed patients often show altered circadian rhythms, sleep disturbances, and diurnal mood variation. Decreased latency of rapid eye movement (REM) sleep, reduction in slow wave sleep, and abnormalities in the timing of REM/nonREM sleep cycles have all been reported in patients with major depressive disorder (MDD). It is thus evident that an understanding of the basic mechanisms of sleep regulation is essential, for a better analysis of the pathophysiology of depressive disorders. The aim of this article is to review progress in understanding the mechanisms that underlie circadian and sleep rhythms, and their role in the treatment of depression. Chronotherapies including, bright light exposure, sleep deprivation, melatonin treatment, and social rhythm therapies, may provide novel insights into the development of new pharmacological and behavioral treatment strategies for mood disorders. The novel antidepressant, agomelatine, which combines the properties of a serotonin 5-HT2C antagonist and a melatonergic MT1/MT2 receptor agonist, has been found to be very effective for resetting the disturbed sleep/wake cycle and improving the clinical status of depressed patients. Agomelatine may fill the gap in the current therapeutic armoury, by combining tolerability profile with efficacy, in treating MDD.
    Biological Rhythm Research 01/2014; 45(1). · 1.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Bright light treatment is effective for seasonal affective disorder (SAD), although the mechanisms of action are still unknown. We investigated whether transcranial bright light via the ear canals has an antidepressant effect in the treatment of SAD.Methods During the four-week study period, 89 patients (67 females; 22 males, aged 22-65, mean¿±¿SD age: 43.2¿±¿10.9 years) suffering from SAD were randomized to receive a 12-min daily dose of photic energy of one of three intensities (1 lumen/0.72 mW/cm2; 4 lumens/2.881 mW/cm2; 9 lumens/6.482 mW/cm2) via the ear canals. The light was produced using light-emitting diodes. The severity of depressive symptoms was assessed with the Hamilton Depression Rating Scale ¿ Seasonal Affective Disorder (SIGH-SAD), the Hamilton Anxiety Rating Scale (HAMA), and the Beck Depression Inventory (BDI). Cognitive performance was measured by the Trail Making Test (TMT). The within-group and between-group changes in these variables throughout the study were analysed with a repeated measures analysis of variance (ANOVA), whereas gender differences at baseline within the light groups were analysed using Student¿s t-tests.ResultsPatients in all three groups showed significant decreases in their BDI, HAMA, and SIGH-SAD scores. Response rates, i.e., an at least 50% decrease of symptoms as measured by the BDI, were 74%-79% in the three treatment groups. Corresponding variations for the SIGH-SAD and the HAMA were 35-45% and 47-62%, respectively. No intensity-based dose-response relationships in the improvement of anxiety and depressive symptoms or cognitive performance between treatment groups were observed. Approximately one in four patients experienced mild adverse effects, of which the most common were headache, insomnia, and nausea.Conclusions These results suggests that transcranial bright light treatment may have antidepressant and anxiolytic effect in SAD patients, as both self- and psychiatrist-rated depressive and anxiety symptoms decreased in all treatment groups. These improvements are comparable to findings of earlier bright light studies that used conventional devices. The lack of dose response may be due to a saturation effect above a certain light intensity threshold. Further studies on the effects of transcranial bright light with an adequate placebo condition are needed.Trial registration NCT01293409,
    BMC Psychiatry 10/2014; 14(1):288. · 2.24 Impact Factor